Recent news has demonstrated they are out performing their own estimates and generating greater cash flow and have some attractive targets to drill up.

Lots of upside potential which seems to be getting some well deserved recognition. With an analyst target of $3.50 and a potential for a real run beyond that if Tumipampa drills serve up some good assays you have to know there is some serious upside here.

With only 9 million floating shares (70% institutional holdings) there isn't much downside risk.